32,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
16 °P sammeln
  • Broschiertes Buch

The book discusses the ability of modified form of wnt5a to carry 4 cisplatin molecules to malignant cells only.Also modified wnt5a will have anti-tumor effect that will reduce many cisplatin resistant mechanisms. Besides that, modified Wnt5a acts as a targeting molecule of cisplatin molecules especially after certain biochemical modifications that will abolish Wnt5a carcinogenic molecular actions, and in the same will enable Wnt5a to load cisplatin without altering its 3rd structure. The book will illustrate carcinogenic molecular actions of endogenous malignant Wnt5a and Wnt based therapies.…mehr

Produktbeschreibung
The book discusses the ability of modified form of wnt5a to carry 4 cisplatin molecules to malignant cells only.Also modified wnt5a will have anti-tumor effect that will reduce many cisplatin resistant mechanisms. Besides that, modified Wnt5a acts as a targeting molecule of cisplatin molecules especially after certain biochemical modifications that will abolish Wnt5a carcinogenic molecular actions, and in the same will enable Wnt5a to load cisplatin without altering its 3rd structure. The book will illustrate carcinogenic molecular actions of endogenous malignant Wnt5a and Wnt based therapies. Also, it will explain the comparison of using modified wnt5a as a therapuetic molecule with other Wnt-based therapuetics from my point of view. The book will discuss in details cisplatin molecular actions, therapuetic uses, different pharmacuetical combination, side effects and different resistance mechanisms against it. The final part of the book is concerned with explanation the methodology of formation cisplatin-Wnt5a molecule and the way of testing its efficacy in comparison to cisplatin.
Autorenporträt
Soy el Dr. Waleed Atta de Egipto. Tengo el grado de maestría, felllowship egipcio en cirugía general y oncología. He publicado un breve artículo de revisión sobre el mismo tema del libro, además del artículo de revisión "Efecto del HIF 1ALPHA modificado unido al inhibidor de la anhidrasa carbónica IX y al cisplatino glicosilado en tumores sólidos".